Conference Roundup

Berotralstat improves quality of life, reduces attacks in patients with hereditary angioedema

Posted on

Patients with hereditary angioedema (HAE) treated with berotralstat experienced sustained decreases in attack frequency and improvements in quality of life, according to data from the APeX-2 and APeX-S clinical trials presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.

After 48 weeks of therapy with 150 mg of oral, once-daily berotralstat, 31 patients in the clinical trial APeX-2 experienced an average of 1.5 attacks per month after one month and 1.0 attack per month at 12 months compared with a mean baseline attack rate of 2.9 attacks per month.

In the clinical trial APeX-S, after 48 weeks of therapy with150 mg of berotralstat, 73 patients had a median attack rate of zero attacks per month in 6 of the 12 months, including month 12.

“As HAE patients continue in our long‑term clinical trials, we are seeing reductions in attack rate and increases in QoL scores which highlight the impact oral, once-daily berotralstat could have in reducing the burden of disease for patients currently dependent on injectable or infused prophylaxis options,” said Dr William Sheridan, chief medical officer of BioCryst, in a press release.

Read more here.


Long-Term Safety and Tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) Prophylaxis: APeX-S Study Results. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress: June 6-8.